Yahoo
NasdaqCM - Nasdaq Real Time Price USD

HeartSciences Inc. (HSCS)

2.8300 +0.1600 (+5.99%)
At close: November 6 at 4:00:01 PM EST
Chart Range Bar
Loading chart for HSCS
Chart does not reflect overnight price.
  • Previous Close 2.6700
  • Open 2.7500
  • Bid 3.2800 x 200
  • Ask 5.4000 x 200
  • Day's Range 2.7500 - 3.0300
  • 52 Week Range 1.6300 - 5.2500
  • Volume 76,632
  • Avg. Volume 163,178
  • Market Cap (intraday) 14.063M
  • Beta (5Y Monthly) 1.81
  • PE Ratio (TTM) --
  • EPS (TTM) -3.2100
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 12.00
  • Zacks Rating Bullish

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

heartsciences.com

14

Full Time Employees

April 30

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HSCS
8.41%
S&P 500 (^GSPC)
7.76%

1-Year Return

HSCS
3.66%
S&P 500 (^GSPC)
9.77%

3-Year Return

HSCS
82.42%
S&P 500 (^GSPC)
68.96%

5-Year Return

HSCS
99.11%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 2.1k
Earnings -3.17M
Profit Margin -151,063.81%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

-3M
-2M
-1M
0
-150000.0%
-100000.0%
-50000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

12.00
12.00 Average
2.8300 Current
12.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/24/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 9.2 -> 8

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -116.44%

  • Return on Equity (ttm)

    -1,851.90%

  • Revenue (ttm)

    4.52k

  • Net Income Avi to Common (ttm)

    -10.26M

  • Diluted EPS (ttm)

    -3.2100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.91k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.24M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: